Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LTR Pharma Limited ( (AU:LTP) ) has issued an update.
LTR Pharma reported continued progress in developing its nasal spray erectile dysfunction therapies, with recruitment for the SPONTAN Phase II pharmacokinetic study now complete and dosing of the final cohort under way, supporting a planned FDA 505(b)(2) pathway. The company also advanced human factors and leachables studies, secured a podium presentation for Phase I SPONTAN data at a major sexual medicine conference, and reported encouraging real-world use, including among younger men with performance-related issues.
In parallel, LTR Pharma is pushing ahead with U.S. commercialisation plans for its ROXUS product via the FDA 503(a) personalised medicine framework, focusing on partner selection and terms while exploring an early-access route. With a debt-free balance sheet and A$24.1 million in cash at 31 March 2026, the group says it is well funded to reach upcoming clinical data readouts, execute its U.S. commercial strategy, and assemble the regulatory packages needed for later-phase trials and potential submissions.
More about LTR Pharma Limited
LTR Pharma Limited is an ASX-listed biopharmaceutical company focused on men’s health, developing and commercialising innovative nasal spray treatments for erectile dysfunction under the SPONTAN and ROXUS brands. The company targets both regulated prescription pathways and personalised medicine routes, with a particular focus on the U.S. market and advancing products through FDA-aligned clinical and regulatory programs.
Average Trading Volume: 189,251
Technical Sentiment Signal: Sell
Current Market Cap: A$70.89M
Learn more about LTP stock on TipRanks’ Stock Analysis page.